Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


The Scottish Medicines Consortium has announce it has approved ocrelizumab (Ocrevus) for the treatment of relapsing remitting multiple sclerosis (RRMS). The drug was approved by NICE for the...
A one-year real world study of Rebif (interferon beta 1-a) has shown that relapsing remitting multiple sclerosis (RRMS) patients experienced high treatment adherence despite seasonal weathers and...
A debate on shared decision making in multiple sclerosis (MS) was led by a patient advocate and leading neurologists from the MS in the 21st Century Steering Group. Chaired by neuropsychologist Dawn...
The National Institute for Health and Care Excellence (NICE) are looking for people with multiple sclerosis (MS) or cancer who have personal experience of using cannabis-derived products for...
A recent Australian study has looked at a new potential treatment being developed for multiple sclerosis (MS), which involves extracting a sample of T-cells from the patient’s own immune system. The...
The US Food & Drugs Administration (FDA) has issued a statement warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse than...
Fampridine, also known as Fampyra, has once again been rejected by the Scottish Medical Consortium (SMC) and will not be made available on the NHS in Scotland to multiple sclerosis (MS) patients with...
Upper limb impairment is common in primary progressive multiple sclerosis (PPMS). A recent study, titled ORATORIO, examined the effects of ocrelizumab on confirmed progression and confirmed...
The MS Trust has confirmed that specialist multiple sclerosis (MS) nurses in the UK are handling heavier caseloads than recommended or preferred and, according to the charity’s latest report, means...
B-cells are important in helping the immune system fight pathogens. However, in the case of multiple sclerosis (MS) they can damage nerve tissue. When particular control cells are missing, too many B...

Pages

Live Chat Software by Click4Assistance UK